Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential

por Barrientos, Jacqueline C
Publicado 2016

Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib

por Shah, Ankit, Barrientos, Jacqueline C
Publicado 2021

Haemophagocytic lymphohistiocytosis following COVID-19 mRNA vaccination

por Wu, Vernon, Lopez, Carlos A, Hines, Adam M, Barrientos, Jacqueline C
Publicado 2022

Henoch-Schönlein purpura presenting post COVID-19 vaccination

por Hines, Adam M., Murphy, Neal, Mullin, Christine, Barillas, Julia, Barrientos, Jacqueline C.
Publicado 2021

Chylothorax in Patients With Chronic Lymphocytic Leukemia: A Case Series

por Sammartino, Daniel, Khanijo, Sameer, Koenig, Seth, Katsetos, John F., Tufano, Andrea, Rai, Kanti R., Barrientos, Jacqueline C.
Publicado 2018

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019

por Kittai, Adam S., Huang, Ying, Bhat, Seema A., Paskett, Electra D., Rogers, Kerry A., Barrientos, Jacqueline C., Fisher, James L., Woyach, Jennifer A.
Publicado 2022

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry

por Mato, Anthony R., Ghosh, Nilanjan, Sharman, Jeff P., Brander, Danielle, Gutierrez, Meghan, Huang, Qing, Wu, Linda H., Young, Alex, Upasani, Sandhya, Naganuma, Maoko, Barrientos, Jacqueline C.
Publicado 2022

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

por Ghia, Paolo, Coutre, Steven E., Cheson, Bruce D., Barrientos, Jacqueline C., Hillmen, Peter, Pettitt, Andrew R., Zelenetz, Andrew D., Shreay, Sanatan, Hallek, Michael, Furman, Richard R.
Publicado 2020

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

por Woyach, Jennifer A., Barr, Paul M., Kipps, Thomas J., Barrientos, Jacqueline C., Ahn, Inhye E., Ghia, Paolo, Girardi, Vincent, Hsu, Emily, Jermain, Mandy, Burger, Jan A.
Publicado 2023

A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice

por Patten, Piers E. M., Ferrer, Gerardo, Chen, Shih-Shih, Kolitz, Jonathan E., Rai, Kanti R., Allen, Steven L., Barrientos, Jacqueline C., Ioannou, Nikolaos, Ramsay, Alan G., Chiorazzi, Nicholas
Publicado 2021

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

por Montillo, Marco, Illés, Árpád, Robak, Tadeusz, Pristupa, Alexander S., Wach, Malgorzata, Egyed, Miklós, Delgado, Julio, Jurczak, Wojciech, Morschhauser, Franck, Schuh, Anna, Eradat, Herbert, Shreay, Sanatan, Barrientos, Jacqueline C., Zelenetz, Andrew D.
Publicado 2019

Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences

por Barrientos, Jacqueline C., Ayed, Ayed O., Cha, Agnes, Du, Senxi, Fang, Bruno, Hall, Ryan, Marks, Stanley M., Peng, Eileen, Rhodes, Joanna M., Ryan, Kellie, Winters, Sharon B., Yeung, Percy L., Hou, Jing-Zhou
Publicado 2023

Characterization of the Intraclonal Complexity of Chronic Lymphocytic Leukemia B Cells: Potential Influences of B-Cell Receptor Crosstalk with Other Stimuli

por Mazzarello, Andrea N., Fitch, Mark, Cardillo, Martina, Ng, Anita, Bhuiya, Sabreen, Sharma, Esha, Bagnara, Davide, Kolitz, Jonathan E., Barrientos, Jacqueline C., Allen, Steven L., Rai, Kanti R., Rhodes, Joanna, Hellerstein, Marc K., Chiorazzi, Nicholas
Publicado 2023

Management of adverse events associated with idelalisib treatment: expert panel opinion

por Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Publicado 2015

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry

por Mato, Anthony R., Barrientos, Jacqueline C., Ghosh, Nilanjan, Pagel, John M., Brander, Danielle M., Gutierrez, Meghan, Kadish, Karen, Tomlinson, Brian, Iyengar, Reethi, Ipe, David, Upasani, Sandhya, Amaya-Chanaga, Carlos I., Sundaram, Murali, Han, Jennifer, Giafis, Nick, Sharman, Jeff P.
Publicado 2019

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

por Coutre, Steven E., Flinn, Ian W., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Wagner-Johnson, Nina D., Sharman, Jeff P., Boyd, Thomas E., Fowler, Nathan, Dreiling, Lyndah, Kim, Yeonhee, Mitra, Siddhartha, Rai, Kanti, Leonard, John P., Furman, Richard R.
Publicado 2018

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis

por O'Brien, Susan M., Byrd, John C., Hillmen, Peter, Coutre, Steven, Brown, Jennifer R., Barr, Paul M., Barrientos, Jacqueline C., Devereux, Stephen, Robak, Tadeusz, Reddy, Nishitha M., Kipps, Thomas J., Tedeschi, Alessandra, Cymbalista, Florence, Ghia, Paolo, Chang, Stephen, Ninomoto, Joi, James, Danelle F., Burger, Jan A.
Publicado 2019

Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course

por Bagnara, Davide, Tang, Catherine, Brown, Jennifer R., Kasar, Siddha, Fernandes, Stacey, Colombo, Monica, Vergani, Stefano, Mazzarello, Andrea N., Ghiotto, Fabio, Bruno, Silvia, Morabito, Fortunato, Rai, Kanti R., Kolitz, Jonathan E., Barrientos, Jacqueline C., Allen, Steven L., Fais, Franco, Scharff, Matthew D., MacCarthy, Thomas, Chiorazzi, Nicholas
Publicado 2021

Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL

por Ferrer, Gerardo, Jung, Byeongho, Chiu, Pui Yan, Aslam, Rukhsana, Palacios, Florencia, Mazzarello, Andrea Nicola, Vergani, Stefano, Bagnara, Davide, Chen, Shih-Shih, Yancopoulos, Sophia, Xochelli, Aliki, Yan, Xiao-Jie, Burger, Jan A., Barrientos, Jacqueline C., Kolitz, Jonathan E., Allen, Steven L., Stamatopoulos, Kostas, Rai, Kanti R., Sherry, Barbara, Chiorazzi, Nicholas
Publicado 2021

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

por Munir, Talha, Brown, Jennifer R., O'Brien, Susan, Barrientos, Jacqueline C., Barr, Paul M., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Kipps, Thomas J., Moreno, Carol, Montillo, Marco, Burger, Jan A., Byrd, John C., Hillmen, Peter, Dai, Sandra, Szoke, Anita, Dean, James P., Woyach, Jennifer A.
Publicado 2019